SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their overall risks ...

Please provide your email address to receive an email when new articles are posted on . Patients with DCIS who received tamoxifen had a lower 15-year risk for ipsilateral breast cancer recurrence.

Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 ...